Skip to content
10-Q

Quarterly Report

EPIZYME, INC.

0000950170-22-008721

← back to feed
Filed
May 10, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 4, 2022 164.87M sh
Shares Diluted Q1 2022 · Mar 31, 2022 144.2K sh
Shares Diluted restated Q1 2022 · Mar 31, 2021 101.79K sh
Capex Q1 2022 · Mar 31, 2022 $10K
Capex Q1 2022 · Mar 31, 2021 $119K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$59.19M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$75.58M
Long Term Debt Q1 2022 · Mar 31, 2022 $216.67M
Long Term Debt Q1 2022 · Dec 31, 2021 $216.46M
Short Term Debt Q1 2022 · Mar 31, 2022 $0
Cash And Equivalents Q1 2022 · Mar 31, 2022 $77.42M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $98.34M
Cash And Equivalents Q1 2022 · Mar 31, 2021 $73.71M
Stockholders Equity Q1 2022 · Mar 31, 2022 $11.12M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$20.69M
Stockholders Equity Q1 2022 · Mar 31, 2021 $123.03M
Stockholders Equity Q1 2022 · Dec 31, 2020 $184.9M
Current Liabilities Q1 2022 · Mar 31, 2022 $38.97M
Current Liabilities Q1 2022 · Dec 31, 2021 $45.2M
Current Assets Q1 2022 · Mar 31, 2022 $228.71M
Current Assets Q1 2022 · Dec 31, 2021 $206.04M
Total Assets Q1 2022 · Mar 31, 2022 $312.19M
Total Assets Q1 2022 · Dec 31, 2021 $289M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.38
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.69
Eps Basic Q1 2022 · Mar 31, 2022 −$0.38
Eps Basic Q1 2022 · Mar 31, 2021 −$0.69
Sga Expense Q1 2022 · Mar 31, 2022 $27.2M
Sga Expense Q1 2022 · Mar 31, 2021 $36.41M
Rd Expense Q1 2022 · Mar 31, 2022 $29.78M
Rd Expense Q1 2022 · Mar 31, 2021 $32.7M
Net Income Q1 2022 · Mar 31, 2022 −$55.51M
Net Income Q1 2022 · Mar 31, 2021 −$70.27M
Operating Income Q1 2022 · Mar 31, 2022 −$50.93M
Operating Income Q1 2022 · Mar 31, 2021 −$64.34M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $2.64M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $2.85M